The company is launching HDx enabled by TheraNova in Australia, New Zealand, France, Germany, Switzerland and Belgium.

The HDx or expanded hemodialysis uses the firm’s Theranova dialyzer to expand the range of molecules, which can be filtered from the blood during therapy.

Theranova dialyzers have been developed for the treatment of chronic and acute renal failure by hemodialysis.

Baxter said the Theranova removes a wide range of middle molecules more effectively than FX CorDiax high-flux dialyzer and can exceed the performance of high-volume HDF for large solutes with moderate albumin removal.

The platform will allow clinics to offer HDx therapy using existing resources, and eliminates the need for special equipment and added clinic workflow that is required for HDF.

HDF is a type of dialysis therapy that will also target larger middle molecules, but it cannot be carried out effectively in all patients.

Baxter Renal president and corporate vice president Giuseppe Accogli said: “Through HDx enabled by Theranova, Baxter is introducing a major advancement in hemodialysis, an area that has seen little improvement in recent years.

“We expect HDx enabled by Theranova to advance hemodialysis care for millions of patients around the world.”

Baxter produces renal and hospital products, including home, acute and in-center dialysis; sterile IV solutions; infusion systems and devices.

Image: Baxter launches HDx therapy enabled by Theranova to provide high performance hemodialysis treatments. Photo: courtesy of Business Wire.